A retrospective cohort study analyzed post-operative outcomes following primary total knee or hip arthroplasty (TKA/THA) comparing patients receiving tirzepatide, a dual GIP/GLP-1 receptor agonist, versus those receiving semaglutide, a selective GLP-1 receptor agonist. The study utilized the TriNetX US Collaborative Network and included adults undergoing TKA or THA with at least two coded prescription fills for either tirzepatide or semaglutide within six months of surgery. Patients taking both agents were excluded. The cohorts were propensity score matched, with 2,858 patients in each group.
Key Clinical Findings
Outcomes were assessed at 90 days, 1 year, and 2 years. Initially, no significant differences were observed in surgical, medical, or implant-related outcomes at 90 days and 1 year. However, at 2 years, exposure to tirzepatide was associated with reduced odds of mechanical complications (OR 0.64, 95% CI 0.42 to 0.96) and periprosthetic joint infection (PJI) (OR 0.64, 95% CI 0.41 to 0.999; P = 0.048). There was no significant difference in reoperation rates (OR 0.68, 95% CI 0.43 to 1.08).
Patient Population and Prevalence
The study indicates that the distinction between dual GIP/GLP-1 agonism and selective GLP-1 agonism may have clinical relevance. Of 669,698 patients who underwent primary TKA or THA, 8,797 (1.3%) had ≥2 tirzepatide or semaglutide prescriptions.